Movement Disorders in Pregnancy

ABSTRACT

Movement disorders are not commonly seen during pregnancy. As a result, there are few studies on whether disease manifestations are affected by the hormonal changes that occur during pregnancy or on the teratogenicity of commonly used medications for movement disorders on the developing fetus. This article discusses movement disorders that are seen only during pregnancy (chorea gravidarum) or that may present during pregnancy (restless legs syndrome), the effect that pregnancy has on symptoms and treatment (in Parkinson's disease, essential tremor, dystonia, tic disorders, and Wilson's disease), and the role of genetic testing for movement disorders in genetic counseling for pregnant women.

Parkinson's disease - tremor - Huntington's disease - dystonia - tics

REFERENCES

• 1 Wilson P, Preece A A. Chorea gravidarum.  Arch Intern Med. 1932;  49 471-533
• 2 Cardoso F. Chorea gravidarum.  Arch Neurol. 2002;  59 868-870
• 3 Donaldson J O. Neurologic emergencies in pregnancy.  Obstet Gynecol Clin North Am. 1991;  18 199-212
• 4 Ichikawa K, Kim R C, Givelber H et al.. Chorea gravidarum. Report of a fatal case with neuropathological observations.  Arch Neurol. 1980;  37 429-432
• 5 Patterson J F. Treatment of chorea gravidarum with haloperidol.  South Med J. 1979;  72 1220-1221
• 6 Golbe L I. Pregnancy and movement disorders.  Neurol Clin. 1994;  12 497-508
• 7 Miller L J. Clinical strategies for the use of psychotropic drugs during pregnancy.  Psychiatr Med. 1991;  9 275-298
• 8 Goldberg H L, Nissim R. Psychotropic drugs in pregnancy and lactation.  Int J Psychiatry Med. 1994;  24 129-147
• 9 Altshuler L L, Szuba M P. Course of psychiatric disorders in pregnancy: dilemmas in pharmacologic management.  Neurol Clin. 1994;  12 613-635
• 10 Miller L J. Psychiatric medication during pregnancy: understanding and minimizing risks.  Psychiatr Ann. 1994;  24 69-75
• 11 Briggs G G, Freeman R K, Yaffe S J. Drugs in Pregnancy and Lactation. 4th ed. Baltimore, MD; Williams & Wilkins 1994
• 12 Sahota P K, Jain S S, Dhand R. Sleep disorders in pregnancy.  Curr Opin Pulm Med. 2003;  9 477-483
• 13 Chokroverty S. Sleep disorders. In: Bradley WG, Daroff RB, Fenichel GM, et al Neurology in Clinical Practice. 3rd ed. Woburn, MA; Butterworth-Heinemann 2000: 1781-1827
• 14 Ekbom K A. Restless legs syndrome.  Neurology. 1960;  10 868-873
• 15 Lang A E. Akathisia and the restless legs syndrome. In: Jankovic J, Tolosa E Parkinson's Disease and Movement Disorders. Baltimore; Williams & Wilkins 1993: 399-418
• 16 Manconi M, Govoni V, DeVito A et al.. Restless legs syndrome and pregnancy.  Neurology. 2004;  63 1065-1069
• 17 Allen R P, Earley C J. Restless legs syndrome: a review of clinical and pathophysiologic features.  J Clin Neurophysiol. 2001;  18 128-147
• 18 O'Keeffe S T, Gavin K, Lavan J N. Iron status and restless legs syndrome in the elderly.  Age Ageing. 1994;  23 200-203
• 19 Winkelman J W, Chertow G M, Lazarus J M. Restless legs syndrome in end-stage renal disease.  Am J Kidney Dis. 1996;  28 372-378
• 20 Iannaccone S, Zucconi M, Marchettini P et al.. Evidence of peripheral axonal neuropathy in primary restless legs syndrome.  Mov Disord. 1995;  10 2-9
• 21 Hening W, Allen R, Earley C et al.. The treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine review.  Sleep. 1999;  22 970-999
• 22 Chesson Jr A L, Wise M, Davila D et al.. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine report.  Sleep. 1999;  22 961-968
• 23 Buelke-Sam J, Byrd R A, Johnson J A, Tizzano J P, Owen N V. Developmental toxicity of the dopamine agonist pergolide mesylate in CD-1 mice: gestational exposure.  Neurotoxicol Teratol. 1991;  13 283-295
• 24 Buelke-Sam J, Byrd R A, Johnson J A, Tizzano J P, Owen N V. Developmental toxicity of the dopamine agonist pergolide mesylate in CD-1 mice. II. Perinatal and postnatal exposure.  Neurotoxicol Teratol. 1991;  13 297-306
• 25 Requip (ropinirole) [product information]. Brentford, United Kingdom; SmithKline Beecham 1996
• 26 Hagell P, Odin P, Vinge E. Pregnancy in Parkinson's disease: a review of the literature and a case report.  Mov Disord. 1998;  13 34-38
• 27 McKeigue P M, Marmot M G. Epidemiology of Parkinson's disease. In: Stern G Parkinson's Disease. London; Chapman and Hall 1990: 295-306
• 28 Bower J H, Maraganore D M, McDonnell S K, Rocca W A. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990.  Neurology. 1999;  52 1214-1220
• 29 Van Den Eeden S K, Tanner C M, Bernstein A L et al.. Incidence of Parkinson's disease: variation by age, gender and race/ethnicity.  Am J Epidemiol. 2003;  157 1015-1022
• 30 Mayeux R, Marder K, Cote L J et al.. The frequency of idiopathic Parkinson's disease by age, ethnic group and sex in northern Manhattan, 1988-1993.  Am J Epidemiol. 1995;  142 820-827
• 31 Saunders-Pullman R, Gordon-Elliott J, Parides M et al.. The effect of estrogen replacement on early Parkinson's disease.  Neurology. 1999;  52 1417-1421
• 32 Pasqualini C, Olivier V, Guibert B et al.. Acute stimulatory effect of estradiol on striatal dopamine synthesis.  J Neurochem. 1995;  65 1651-1657
• 33 Xiao L, Becker J B. Effects of estrogen agonists on amphetamine-stimulated striatal dopamine release.  Synapse. 1998;  29 379-391
• 34 Disshon K A, Boja J W, Dluzen D E. Inhibition of striatal dopamine transporter activity by 17beta-estradiol.  Eur J Pharmacol. 1998;  345 207-211
• 35 Disshon K A, Dluzen D E. Use of in vitro superfusion to assess the dynamics of striatal dopamine clearance: influence of estrogen.  Brain Res. 1999;  842 399-407
• 36 Levesque D, DiPaolo T. Modulation by estradiol and progesterone of the GTP effect on striatal D2 dopamine receptors.  Biochem Pharmacol. 1993;  45 723-733
• 37 Roy E J, Buyer D R, Licari V A. Estradiol in the striatum: effects on behavior and dopamine receptors but no evidence for membrane steroid receptors.  Brain Res Bull. 1990;  25 221-227
• 38 Hruska R E, Ludmer L M, Pitman K T et al.. Effects of estrogen on striatal dopamine receptor function in male and female rats.  Pharmacol Biochem Behav. 1982;  16 285-291
• 39 Dluzen D E. Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system.  J Neurocytol. 2000;  29 387-399
• 40 Morissette M, Di Paolo T. Effect of chronic estradiol and progesterone treatments of ovariectomized rats on brain dopamine uptake sites.  J Neurochem. 1993;  60 1876-1883
• 41 Bazzett T J, Becker J B. Sex differences in the rapid and acute effects of estrogen on striatal D2 dopamine receptor binding.  Brain Res. 1994;  637 163-172
• 42 Lammers C H, D'Souza U, Qin Z H, Lee S H, Yajima S, Mouradian M M. Regulation of striatal dopamine receptors by estrogen.  Synapse. 1999;  34 222-227
• 43 Horstink M W, Strijks E, Dluzen D E. Estrogen and Parkinson's disease.  Adv Neurol. 2003;  91 107-114
• 44 Quinn N P, Marsden C D. Menstrual-related fluctuations in Parkinson's disease.  Mov Disord. 1986;  1 85-87
• 45 Sandyk R. Estrogens and the pathophysiology of Parkinson's disease.  Int J Neurosci. 1989;  45 119-122
• 46 Tsang K L, Ho S L, Lo S K. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations.  Neurology. 2000;  54 2292-2298
• 47 Blanchet P J, Fang J, Hyland K et al.. Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study.  Neurology. 1999;  53 91-95
• 48 Kompoliti K, Comella C L, Jaglin J A et al.. Menstrual-related changes in motoric function in women with Parkinson's disease.  Neurology. 2000;  55 1572-1575
• 49 Strijks E, Kremer J A, Horstink M W. Effects of female sex steroids on Parkinson's disease in postmenopausal women.  Clin Neuropharmacol. 1999;  22 93-97
• 50 Shulman L M, Minagar A, Weiner W J. The effect of pregnancy in Parkinson's disease.  Mov Disord. 2000;  15 132-135
• 51 Mucchiut M, Belgrado E, Cutuli D, Antonini A, Bergonzi P. Pramipexole-treated Parkinson's disease during pregnancy.  Mov Disord. 2004;  19 1114-1115
• 52 Staples R E, Mattis P A. Teratology of L-dopa.  Teratology. 1973;  8 238
• 53 Merchant C A, Cohen G, Mytilineou C et al.. Human transplacental transfer of carbidopa/levodopa.  J Neural Transm Park Dis Dement Sect. 1995;  9 239-242
• 54 Scott M, Chowdhury M. Pregnancy in Parkinson's disease: unique case report and review of the literature.  Mov Disord. 2005;  20 1078-1079
• 55 Benito-Leon J, Bermejo F. Pregnancy in Parkinson's disease: a review of the literature and a case report.  Mov Disord. 1999;  14 194
• 56 Mari M, De Zenzola A, Lamberti P. Antiparkinsonian treatment in pregnancy.  Mov Disord. 2002;  17 428-429
• 57 Kupsch A, Oertel W H. Selegiline, pregnancy and Parkinson's disease.  Mov Disord. 1998;  13 175-176
• 58 Whitaker-Azmitia P M, Zhang X, Clarke C. Effects of gestational exposure to monamine oxidase inhibitors in rats: preliminary behavioral and neurochemical studies.  Neuropsychopharmacology. 1994;  11 125-132
• 59 Eldepryl (selegiline) [product information]. Tampa, FL; Somerset Pharmaceutical 1996
• 60 Nora J J, Nora A H, Way G L. Cardiovascular maldevelopment associated with maternal exposure to amantadine [letter].  Lancet. 1975;  2 607
• 61 Tanner C M, Goldman S M. Epidemiology of movement disorders.  Curr Opin Neurol. 1994;  7 340-345
• 62 Hubble J P, Busenbark K L, Koller W C. Essential tremor.  Clin Neuropharmacol. 1989;  12 453-482
• 63 Leehey M A. Tremor: diagnosis and treatment.  Prim Care Case Rev. 2001;  4 32-39
• 64 Connor G S. A double blind placebo-controlled trial of topiramate treatment for essential tremor.  Neurology. 2002;  59 132-134
• 65 Louis E D. Essential tremor.  N Engl J Med. 2001;  345 887-891
• 66 Palmieri C, Raffaele C. Teratogenic potential of the newer antiepileptic drugs.  CNS Drugs. 2002;  16 755-764
• 67 Glauser T A. Topiramate.  Epilepsia. 1999;  40(suppl 5) S71-S80
• 68 Hoyme H E, Hauck L, Quinn D. Minor anomalies accompanying prenatal exposure to topiramate [abstract].  J Investig Med. 1998;  45 119A
• 69 Ohman I, Sigurd V, Luef G et al.. Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations.  Epilepsia. 2002;  43 1157-1160
• 70 McLean M J. Gabapentin in the management of convulsive disorders.  Epilepsia. 1999;  40(suppl 6) S39-S50
• 71 Bar-Oz B, Nulman I, Koren G, Ito S. Anticonvulsants and breast feeding: a critical review.  Paediatr Drugs. 2000;  2 113-126
• 72 Bressman S B, de Leon D, Brin M F et al.. Idiopathic torsion dystonia among Ashkenazi Jews: Evidence for autosomal dominant inheritance.  Ann Neurol. 1989;  26 612-620
• 73 Rogers J D, Fahn S. Movement disorders and pregnancy. In: Devinsky O, Feldman E, Hainline B Neurological Complications of Pregnancy (Advances in Neurology, Vol. 64). New York; Raven Press 1994: 163-178
• 74 Lim E C, Seet R C, Wilder-Smith E P, Ong B K. Dystonia gravidarum: a new entity?.  Mov Disord. 2006;  21 69-70
• 75 Nomoto M, Kaseda S, Iwata S et al.. Levodopa in pregnancy.  Mov Disord. 1997;  12 261
• 76 Ball M C, Sagar H J. Levodopa in pregnancy.  Mov Disord. 1995;  10 115
• 77 Myobloc (botulinum toxin type B) [product information]. South San Francisco, CA; Elan Pharmaceuticals 2004
• 78 Botox (botulinum toxin type A) [product information]. Irvine, CA; Allergan 2006
• 79 Newman W J, Davis T L, Padaliya B B et al.. Botulinum toxin type A therapy during pregnancy.  Mov Disord. 2004;  19 1384-1385
• 80 Morgan J C, Iyer S S, Moser E T et al.. Botulinum toxin A during pregnancy: a survey of treating physicians.  J Neurol Neurosurg Psychiatry. 2006;  77 117-119
• 81 Bruun R D, Budman C L. The natural history of Tourette syndrome.  Adv Neurol. 1992;  58 1-6
• 82 Keen-Kim D, Freimer N B. Genetics and epidemiology of Tourette syndrome.  J Child Neurol. 2006;  21 665-671
• 83 Schwabe M J, Konkol R J. Menstrual cycle-related fluctuations of tics in Tourette's syndrome.  Pediatr Neurol. 1992;  8 43-46
• 84 Robertson M M. The Gilles de la Tourette syndrome: the current status.  Br J Psychiatry. 1989;  154 147-169
• 85 Shapiro A K, Shapiro E. Tourette syndrome: clinical aspects, treatment, and etiology.  Semin Neurol. 1982;  2 373-385
• 86 Hyde T M, Weinberger D R. Tourette's syndrome: a model neuropsychiatric disorder.  JAMA. 1995;  273 498-501
• 87 The Tourette's Syndrome Study Group . Treatment of ADHD in children with tics: a randomized controlled trial.  Neurology. 2002;  58 527-536
• 88 American Academy of Pediatrics . Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn.  Pediatrics. 2000;  105 880-887
• 89 Auerbach J G, Hans S L, Marcus J, Maeir S. Maternal psychotropic medication and neonatal behavior.  Neurotoxicol Teratol. 1992;  14 399-406
• 90 Frydman M, Bonne-Tamir B, Farrer L A et al.. Assignment of the gene for Wilson's disease to chromosome 13.  Proc Natl Acad Sci USA. 1985;  82 1819-1821
• 91 Bull P C, Thomas G R, Rommens J M et al.. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes's gene.  Nat Genet. 1993;  5 327-337
• 92 Tanzi R E, Petrukhin K, Chernov I et al.. The Wilson's disease gene is a copper transporting ATPase with homology to the Menke's disease gene.  Nat Genet. 1993;  5 344-350
• 93 Yamaguchi Y, Heiny M E, Gitlin J D. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease.  Biochem Biophys Res Commun. 1993;  197 271-277
• 94 Pfeil S A, Lynn D J. Wilson's disease: Copper unfettered.  J Clin Gastroenterol. 1999;  29 22-31
• 95 Bonne-Tamir B, Frydman M, Agger M S et al.. Wilson's disease in Israel: a genetic and epidemiological study.  Ann Hum Genet. 1990;  54 155-168
• 96 Sinha S, Taly A B, Prashanth L K et al.. Successful pregnancies and abortions in symptomatic and asymptomatic Wilson's disease.  J Neurol Sci. 2004;  217 37-40
• 97 Oga M, Matsui N, Anai T et al.. Copper deposition of the fetus and placenta in a patient with untreated Wilson's disease.  Am J Obstet Gynecol. 1993;  169 196-198
• 98 Brewer G J, Askari F, Lorincz M T et al.. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.  Arch Neurol. 2006;  63 521-527
• 99 Berghella V, Steele D, Spector T et al.. Successful pregnancy in a neurologically impaired woman with Wilson's disease: case report.  Am J Obstet Gynecol. 1997;  176 712-714
• 100 Dupont P, Irion O, Beguin F. Pregnancy in a patient with treated Wilson's disease: a case report.  Am J Obstet Gynecol. 1990;  163 1527-1528
• 101 Went L, Broholm J, Cassiman J J et al.. Guidelines for the molecular genetics predictive test in Huntington disease.  J Med Genet. 1994;  31 555-559
• 102 Lesca G, Goizet C, Durr A. Predictive testing in the context of pregnancy: experience in Huntington's disease and autosomal dominant cerebellar ataxia.  J Med Genet. 2002;  39 522-525
• 103 Gusella J F, Wexler N S, Conneally P M et al.. A polymorphic DNA marker genetically linked to Huntington's disease.  Nature. 1983;  306 234-238
• 104 Huntington's Disease Collaborative Research Group . A novel gene containing a trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes.  Cell. 1993;  72 971-983
• 105 Hayden M R. Predictive testing for Huntington's disease: a universal model?.  Lancet Neurol. 2003;  2 141-142
• 106 Goizet C, Lesca G, Durr A. Presymptomatic testing in Huntington's disease and autosomal dominant cerebellar ataxias.  Neurology. 2002;  59 1330-1336
• 107 Moutou C, Gardes N, Viville S. New tools for preimplantation genetic diagnosis of Huntington's disease and their clinical applications.  Eur J Hum Genet. 2004;  12 1007-1014
• 108 Quinn N, Schrag A. Huntington's disease and other choreas.  J Neurol. 1998;  245 709-716